Daniel A. Harki

3.5k total citations · 1 hit paper
77 papers, 2.6k citations indexed

About

Daniel A. Harki is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Daniel A. Harki has authored 77 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 17 papers in Infectious Diseases and 12 papers in Virology. Recurrent topics in Daniel A. Harki's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and Viral Infections and Immunology Research (10 papers). Daniel A. Harki is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and Viral Infections and Immunology Research (10 papers). Daniel A. Harki collaborates with scholars based in United States, Netherlands and Switzerland. Daniel A. Harki's co-authors include John C. Widen, Kay M. Brummond, Paul Jackson, Reuben S. Harris, Margaret E. Olson, Michael I. Luster, Petia P. Simeonova, Blake R. Peterson, Peter B. Dervan and Joseph K. Hexum and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Daniel A. Harki

73 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions

2016 407 citations Paul Jackson, John C. Widen et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel A. Harki United States	28	1.6k	422	371	280	255	77	2.6k
Shridhar Bhat United States	21	1.5k 1.0×	403 1.0×	333 0.9×	331 1.2×	148 0.6×	37	2.6k
Mattia Mori Italy	28	1.7k 1.0×	596 1.4×	262 0.7×	306 1.1×	125 0.5×	152	2.6k
Aiming Sun United States	29	947 0.6×	401 1.0×	156 0.4×	151 0.5×	114 0.4×	42	2.1k
Dennis E. Danley United States	31	2.7k 1.7×	476 1.1×	405 1.1×	385 1.4×	644 2.5×	52	4.1k
Lars Petter Jordheim France	27	1.7k 1.1×	524 1.2×	597 1.6×	627 2.2×	222 0.9×	109	3.1k
Peter A. Beal United States	38	4.8k 3.0×	407 1.0×	176 0.5×	252 0.9×	387 1.5×	117	5.4k
Millie M. Georgiadis United States	28	2.5k 1.5×	207 0.5×	441 1.2×	360 1.3×	110 0.4×	79	3.3k
Jean‐Pierre Falgueyret Canada	32	1.4k 0.9×	960 2.3×	130 0.4×	295 1.1×	312 1.2×	73	3.0k
Scott D. Larsen United States	37	1.8k 1.1×	988 2.3×	333 0.9×	365 1.3×	165 0.6×	102	3.6k
Balkrishen Bhat United States	34	3.3k 2.0×	258 0.6×	524 1.4×	270 1.0×	1.2k 4.6×	94	4.6k

Countries citing papers authored by Daniel A. Harki

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Harki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Harki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Harki more than expected).

Fields of papers citing papers by Daniel A. Harki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Harki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Harki. The network helps show where Daniel A. Harki may publish in the future.

Co-authorship network of co-authors of Daniel A. Harki

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Harki. A scholar is included among the top collaborators of Daniel A. Harki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Harki. Daniel A. Harki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aihara, Hideki, et al.. (2025). A Novel Fluorescence Polarization Binding Assay for the Main Protease (M ^pro ) of SARS-CoV-2. ACS Pharmacology & Translational Science. 8(11). 4055–4069.

Moorthy, Ramkumar, et al.. (2025). Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase. ACS Chemical Biology. 20(11). 2593–2600.

Harki, Daniel A., et al.. (2025). Identification of a novel allosteric binding site on the catalytic domain of NF-κB inducing kinase (NIK). RSC Medicinal Chemistry. 16(4). 1681–1685. 1 indexed citations

Sawyer, Jacob M., et al.. (2024). Development of 3′-Deoxy-3′,4′-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses. ACS Medicinal Chemistry Letters. 15(8). 1334–1339. 2 indexed citations

Das, Sourav, Clifford T. Gee, Sergio C. Chai, et al.. (2023). Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors. ACS Medicinal Chemistry Letters. 14(10). 1441–1447. 2 indexed citations

Harki, Daniel A., et al.. (2023). Recent progress and structural analyses of domain‐selective BET inhibitors. Medicinal Research Reviews. 43(4). 972–1018. 20 indexed citations

Srivastava, Pankaj, Thomas K. Anderson, Ibrahim M. Moustafa, et al.. (2022). Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease. Nucleic Acids Research. 51(1). 315–336. 11 indexed citations

Cui, Huarui, Elizabeth C. Griffith, Clifford T. Gee, et al.. (2022). A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of Medicinal Chemistry. 65(3). 2342–2360. 23 indexed citations

Moorthy, Ramkumar, et al.. (2022). Expanding Catch and Release DNA Decoy (CRDD) Technology with Pyrimidine Mimics. Chemistry - A European Journal. 28(58). e202201355–e202201355. 1 indexed citations

10.

Ngo, Kiet, Jamie J. Arnold, Anoop Narayanan, et al.. (2021). A Chemical Strategy for Intracellular Arming of an Endogenous Broad-Spectrum Antiviral Nucleotide. Journal of Medicinal Chemistry. 64(20). 15429–15439. 6 indexed citations

11.

Shi, Ke, Surajit Banerjee, Jennifer L. McCann, et al.. (2021). Structural basis for recognition of distinct deaminated DNA lesions by endonuclease Q. Proceedings of the National Academy of Sciences. 118(10). 13 indexed citations

12.

Moorthy, Ramkumar, et al.. (2021). An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir. RSC Advances. 11(50). 31373–31376. 2 indexed citations

13.

Jackson, Paul, John C. Widen, Matthew E. Cuellar, et al.. (2020). Synthesis of Guaianolide Analogues with a Tunable α-Methylene−γ-lactam Electrophile and Correlating Bioactivity with Thiol Reactivity. Journal of Medicinal Chemistry. 63(23). 14951–14978. 19 indexed citations

14.

Cui, Huarui, Anil K. Pandey, Ke Shi, et al.. (2020). Selective N‐Terminal BET Bromodomain Inhibitors by Targeting Non‐Conserved Residues and Structured Water Displacement**. Angewandte Chemie International Edition. 60(3). 1220–1226. 36 indexed citations

15.

Kvach, Maksim V., Lorraine Sutton, John P. Donahue, et al.. (2019). Differential Inhibition of APOBEC3 DNA‐Mutator Isozymes by Fluoro‐ and Non‐Fluoro‐Substituted 2′‐Deoxyzebularine Embedded in Single‐Stranded DNA. ChemBioChem. 21(7). 1028–1035. 15 indexed citations

16.

Mishra, Neeraj K., Huarui Cui, John C. Widen, et al.. (2018). Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase–Bromodomain Inhibitor. Journal of Medicinal Chemistry. 61(20). 9316–9334. 51 indexed citations

17.

Harki, Daniel A., et al.. (2018). 4-Cyanoindole-2′-deoxyribonucleoside (4CIN): A Universal Fluorescent Nucleoside Analogue. Organic Letters. 20(14). 4310–4313. 20 indexed citations

18.

Wagner, Jeffrey, Özlem Demir, Michael A. Carpenter, et al.. (2018). Determinants of Oligonucleotide Selectivity of APOBEC3B. Journal of Chemical Information and Modeling. 59(5). 2264–2273. 11 indexed citations

19.

Widen, John C., et al.. (2018). SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. Bioconjugate Chemistry. 29(4). 1111–1118. 16 indexed citations

20.

Widen, John C., Aaron Kempema, Peter W. Villalta, & Daniel A. Harki. (2016). Targeting NF-κB p65 with a Helenalin Inspired Bis-electrophile. ACS Chemical Biology. 12(1). 102–113. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact